Klaria Pharma Holding AB (DE:6FN)
FRANKFURT:6FN
Want to see DE:6FN full AI Analyst Report?
6FN Stock Chart & Stats
€0.06
>-€0.01(-25.00%)
At close: 4:00 PM EST
€0.06
>-€0.01(-25.00%)
Day’s Range― - ―
52-Week Range€0.03 - €0.12
Previous CloseN/A
Volume0.00
Average Volume (3M)8.58K
Market Cap
€17.85M
Enterprise Value€268.13M
Total Cash (Recent Filing)€342.00K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding245,976,150
10 Day Avg. Volume650
30 Day Avg. Volume8,579
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-31.79
Price to Sales (P/S)13.71
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€2.22M
Bulls Say, Bears Say
Bulls Say
Proprietary Delivery PlatformKlaria’s mucoadhesive oral film is a durable product differentiation: the platform enables rapid systemic uptake and can serve multiple indications. Over months this supports licensing, targeted partnerships, and a focused go-to-market strategy that can scale without rebuilding core R&D capabilities.
Debt ReductionReporting zero total debt in 2025 materially reduces interest burden and near-term covenant pressure versus prior elevated leverage. This improves financing flexibility and reduces fixed costs, making external capital raises less encumbered and supporting clinical/commercial planning over the medium term.
Historical Revenue Upside MetricA very high historical revenue-growth metric indicates the business has demonstrated the ability to generate material top-line expansion in past periods. If management can stabilize growth drivers this suggests meaningful commercial or partnership potential that could be monetized over coming quarters.
Bears Say
Persistent Operating LossesThe company has sustained large operating losses and very negative net margins, which erode retained capital and limit reinvestment. Continued unprofitability increases reliance on external funding, heightens dilution risk, and constrains the ability to scale commercialization or sustain multi-indication development over months.
Negative Shareholders' EquityNegative equity is a structural balance-sheet red flag that reduces financial flexibility. It can impede access to traditional financing, complicate partner deals, and signal accumulated losses or dilution; resolving it typically requires recapitalization, a material event that shapes strategic options over the medium term.
Recurring Negative Operating Cash FlowConsistent negative operating cash flow and a sharp 2025 outflow indicate the business is not self-funding. This creates ongoing liquidity and execution risk, forcing reliance on dilutive financings or partnerships to fund clinical programs and commercialization, which can hinder long-term strategic control.
6FN FAQ
What was Klaria Pharma Holding AB’s price range in the past 12 months?
Klaria Pharma Holding AB lowest stock price was €0.03 and its highest was €0.12 in the past 12 months.
What is Klaria Pharma Holding AB’s market cap?
Klaria Pharma Holding AB’s market cap is €17.85M.
When is Klaria Pharma Holding AB’s upcoming earnings report date?
Klaria Pharma Holding AB’s upcoming earnings report date is Aug 21, 2026 which is in 87 days.
How were Klaria Pharma Holding AB’s earnings last quarter?
Currently, no data Available
Is Klaria Pharma Holding AB overvalued?
According to Wall Street analysts Klaria Pharma Holding AB’s price is currently Overvalued.
Does Klaria Pharma Holding AB pay dividends?
Klaria Pharma Holding AB does not currently pay dividends.
What is Klaria Pharma Holding AB’s EPS estimate?
Klaria Pharma Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Klaria Pharma Holding AB have?
Klaria Pharma Holding AB has 245,976,150 shares outstanding.
What happened to Klaria Pharma Holding AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Klaria Pharma Holding AB?
Currently, no hedge funds are holding shares in DE:6FN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Klaria Pharma Holding AB
Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy. The company's clinical phase products include Epinephrine/Adrenaline for the treatment of acute allergic reaction; Naloxone for opioid overdose; and Ketamine for acute pain and depression. It also focuses on the commercialization of cannabis/cannabinoids, including THC and CBD for medical and recreational applications. The company was founded in 2014 and is based in Uppsala, Sweden.